Form 4: Eli Lilly Director Acquires Stock Units

Eli Lilly & Co. Director Gabrielle Sulzberger acquired 7.103 common stock units at $698.05 per unit as part of a deferred compensation plan.

Summary

• Director Gabrielle Sulzberger acquired 7.103 shares of Eli Lilly & Co. common stock.
• The acquisition price was $698.05 per share.
• The transaction date is August 18, 2025.
• These shares were acquired in lieu of cash compensation under the Lilly Directors' Deferral Plan.
• The shares will be settled as common stock following the reporting person's separation from service.
• Following this transaction, the director will beneficially own 2,710.158 shares directly.

Sentiment

Score: 7

Explanation: The acquisition of shares by a director, even as part of a compensation plan, generally indicates alignment of interests and confidence in the company's long-term prospects. While not a discretionary purchase, it still adds to insider ownership.

Positives

• Director Gabrielle Sulzberger is increasing her beneficial ownership in the company, aligning her interests with shareholders.
• The acquisition is part of a deferred compensation plan, indicating a structured approach to long-term incentive for directors.

Negatives

• The acquisition is not a discretionary open-market purchase, but rather part of a compensation plan, which may temper the signal of strong insider conviction.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• The transaction involves a director acquiring shares from the company as part of a compensation plan, which is a common form of related-party transaction in corporate governance.

Stakeholder Impact

• Shareholders: Increased alignment of director's interests with shareholder value through equity ownership.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• Settlement of stock units into common stock following the reporting person's separation from service.

Key Dates

Recommendation

While the director's acquisition of shares is a positive signal of alignment, it is part of a routine compensation plan rather than a discretionary open-market purchase. This type of transaction, while beneficial for long-term alignment, does not typically warrant a 'buy' recommendation on its own. It reinforces a 'hold' position for investors already confident in Eli Lilly's fundamentals.

Keywords

Eli Lilly, LLY, Form 4, Insider Trading, Director Compensation, Stock Units, Deferred Compensation, Pharmaceuticals, Biotech